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RÉSUMÉ 
Contexte: Les déclarations spontanées révèlent des différences entre les sexes en ce qui a 
trait aux effets de nature cardiaque associés à l'érythromycine, un macrolide couramment 
prescrit. On ignore si des effets similaires se manifestent avec les macrolides plus 
récents: en l'occurrence, l'azithromycine et la clarithromycine. 
Objectifs: i) évaluer le lien entre les manifestations cardiaques rapportées et la prise . 
d'azithromycine ou de clarithromycine; ii) déterminer si le sexe du patient a une 
incidence sur ce lien; iii) établir si les différences entre les sexes pourraient plutôt être 
attribuables à des schémas d'utilisation différents en contexte réel. 
Méthodes: On a appliqué la méthode de déclaration proportionnelle à la base de données 
des déclarations spontanées de la Food and Drug Administration (FDA) des États-Unis. 
Les « cas» étaient les déclarations de manifestations cardiaques, et les « non-cas », les 
déclarations de manifestations indésirables de d'autre nature. Tout les rapports d'effets 
indésirables ont été consideré al' exception des rapports de consommateurs recensée 
durant la période du 1er janvier 1992 et le 31 décembre 1997 (période de déclaration de 
pointe). 
Afin d'établir si les différences entre les sexes pouvaient être attribuables à des schémas 
d'utilisation différents, on a mené une sous-étude auprès de la Régie de l'assurance-
maladie du Québec (RAMQ), en supposant que les différences entre les sexes dans les 
schémas d'utilisation seraient similaires aux différences observées aux États-Unis, c'est-
à-dire la population ciblée par la base de données de pharmacovigilance de la FDA. 
Résultats: Au total, 248 230 déclarations de la base de données de pharmacovigilance de 
la FDA répondaient aux critères d'admissibilité. Après ajustement selon l'âge, le rapport 
de déclaration proportionnel était de 1,03 (lC à 95 % : 0,80 - 1,33) pour l'azithromycine 
et de 1,02 (0,90 - 1,15) pour la clarithromycine. Pour l'azithromycine, le rapport chez les 
hommes était de 0,77 (0,53 - 1,11), et chez les femmes il était de 1,36 (0,96 - 1,92). Pour 
la clarithromycine, il était de 0,88 (0,73 - 1,06) chez les hommes, et de 1,17 ( 0,99 -
1,38) chez les femmes. La sous-étude (n = 4000) effectuée à partir de la base de données 
de la RAMQ n'a révélé aucune différence entre les sexes dans les schémas d'utilisation 
des médicaments (durée du traitement et posologie) ou les caractéristiques des patients 
tels que leurs antécédents médicaux. 
Conclusion: On a constaté une tendance voulant que le sexe ait une influence sur la 
mesure de l'association (les évaluations ponctuelles étaient plus élevées chez les 
femmes). Par contre, compte tenu de la rareté des manifestations, on n'a pu mettre en 
évidence de différence statistiquement significative entre les sexes quant à la déclaration 
des effets de nature cardiaque. On se penche sur les avantages et les limites de la méthode' 
utilisée. 
Mots clés: Réaction indésirable, cas, base de données de pharmacovigilance, 
déclarations spontanées, manifestations cardiaques, différences entre les sexes, 
antibiotique, érythromycine, clarithromycine, azithromycine. 
ABSTRACT 
Background: Gender differences in cardiac effects associated with the commonly 
prescribed macrolide antibiotic, erythromycin, have been noted in spontaneous reports. It 
is not known whether similar effects are present with the newer macrolides: 
azithromycin and clarithromycin. 
Objectives: i) To assess the association between azithromycin, clarithromycin and the 
reporting of cardiac events; ii) To determine whether the association is modified by 
gender; iii) To'determine whether gender differences could be confounded by differences 
in patterns of drug use in a real-life setting. 
Methods: The proportional reporting method applied to the United States Food & Drug 
Administration (FDA) spontaneous reporting database was used. The cases were reports 
of cardiac events and the non-cases were reports of other adverse effects. Ali reports, 
excluding consumerreports, from January 1 st 1992 to December 31 st 1997 (peak 
reporting period) were considered . 
. In order to determine whether gender differences in cardiac reporting rates could be 
confounded by differences in patterns of drug use, a sub-study was conducted using the 
Régie de l'Assurance-Maladie du Quebec (RAMQ), under assumption that gender 
differences in patterns of drug use would be similar to those found in the US, i.e. the 
population targeted by the FDA pharmacovigilance database. 
Results: From the FDA pharmacovigilance database, 248, 230 reports met the eligibility 
criteria. Adjusting for age, the proportional reporting ratio was 1.03 (95%CI: 0.80-1.33) 
for azithromycin and 1.02 (0.90 to 1.15) for clarithromycin. For azithromycin, the ratio 
for men was 0.77 (0.53 toI. 11) and for women was 1.36 (0.96 to 1.92). For 
clarithromycin, the ratio for men was 0.88 (0.73 to 1.06) and for women was 1.17 (0.99 
to 1.38). The sub-study (n=4000) conducted with the RAMQ database revealed no 
differences across genders in patterns of drug use (i.e. duration and dosage) or patient 
characteristics such as medical history. 
Conclusion: There was a trend that gender modified the measure of association (point 
estimates were greater for females than males), however, due to the rarity of exposed 
events, a statistically significant gender difference in the reporting of cardiac events could 
not be found in this study. Advantages and limitations of the method are discussed. 
Key Words: 
Adverse Reaction, Cases, Pharmacovigilance Database, Spontaneous Reports, Cardiac 
Events, Gender difference, Antibiotic, Erythromycin, Clarithromycin, Azithromycin 
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1. Introduction 
Presently, two macrolides, Zithromax® (azithromycin) and Biaxin® (c1arithromycin) 
are being marketed worldwide and used by millions of individuals. Cardiac effects 
associated with erythromycin, an older generation antibiotic also extensively used, 
have been reported to various pharmacovigilance systems, with reporting rates that 
appear to differ across genders [1]. It is not known, however, whether the gender 
differences in reporting rates indicate gender differences in risks, or whether they are 
confounded by factors su ch as prescription channeling or patterns of use [1, 2]. At 
present, it is not known whether azithromycin or c1arithromycin, similar in drug c1ass 
to erythromycin, are also associated with cardiac effects and if there are any gender 
differences. 
In a study (n=63), results showed erythromycin therapy was associated with 
prolongation of myocardial repolarization which manifested after the first few doses 
in a majority of patients [1]. Erythromycin is a widely used antibiotic for which 
lengthening of the rate-corrected QT interval (QTc) on the electrocardiogram (ECG) 
has been reported inc1uding torsades de pointes (TdP) [1,2,3,4]. In a separate study 
(n=278), occurrence of QT prolongation (~ 440 msec), inc1uding severe prolongation 
(~ 560 msec), due to erythromycin was common. In 1998, using the FDA 
MEDW A TCH database and in vitro experiment, Drici M. et al. [1] observed that 
female gender was a risk factor for cardiac arrhythmias associated with erythromycin. 
In this study, the Food and Drug Administration (FDA) Spontaneous Reporting 
2 
System (SRS) was searched to identify adverse drug reaction reports associated with 
erythromycin products between 1970 and 1996. The terms searched were 
cardiovascular arrhythmias, such as ventricular fibrillation, torsades de pointes (TdP), 
heart arrest, tachycardia, bradycardia, atrioventricular blocks, extrasystoles, QT 
interval prolongation, ECG abnormalities, and combinations of these terms. The 
reports were c1assified according to the sex and age of the patient. The following 
incidents of cardiac arrhythmias (n = 346) involving erythromycin products were 
reported via the FDA SRS; 201 females (58%), 110 males (32%), and 35 unspecified 
(10%). Forty-nine were life-threatening ventricular arrhythmias and deaths directly 
related to intravenous erythromycin lactobionate: 33 women (67%) and 16 men 
(33%) (P=.03). During the same period, no gender imbalance was present in the 
prescription pattern for intravenous erythromycin lactobionate (men 47%, women 
49%, unspecified 4%) [1]. 
Within the same study, an in vitro model was then used to examine a potential sex 
difference in the effect of erythromycin on the QTc interval of isolated perfused 
rabbit hearts. Increasing concentrations of erythromycin lactobionate at 1, 10, and 
100 IlmollL were added for successive periods of 40 minutes to study the QTc 
response at concentrations similar to the range reached in plasma during clinical 
therapy (10-50 Il mo lIL ). Results showed perfusion with erythromycin caused 
significantly greater QT -prolongation in female rabbit hearts (mean [SD], II.8% 
[2.3%]) than in male hearts (6.9% [2.1 %]; P=.03) [1]. Based on in vitro experiments, 
a sex difference in cardiac repolarization response to erythromycin appears to be a 
3 
potential contributing factor. [1, 2, 5, 6]. Therefore, as in humans, it appears that clear 
gender differences exist in the electrophysiological characteristics governing cardiac 
repolarization in rabbits. 
The objective of this research project was to assess, through the FDA spontaneous 
reporting database, the association between azithromycin and clarithromycin and the 
reporting of cardiac events and to determine whether the association is modified by 
gender. AIso, a population-based utilization study was conducted as a sub-study in 
order to determine whether gender differences in cardiac reporting rates could be 
explained by differences in patterns of drug use in a "real-life" setting. 
There is theoretical evidence that suggests that gender may be an important variable 
in the processes of absorption, distribution, metabolism and excretion of medicines 
[5]. Although data to support such hypotheses are limited, the first chapter of the 
thesis provides a review of the evidence that supports differences in the 
pathophysiological factors that may induce gender differences in risks of adverse 
effects. Differences in the proportion of lean body mass and adipose tissue, gastric 
acid secretion, hormonally-induced alterations of protein binding, and gender-specific 
cytochrome P450 isozymes, to name a few, have been suggested to be responsible for 
such differences [5, 7]. Gender differences in pharmacokinetic factors indicate that, 
overall, women will achieve higher plasma drug concentrations than their male 
counterparts [8]. The impact of these differences on the risk of adverse events 
associated with drug use in "real-life" conditions remains largely unexplored to date. 
4 
It is evident, therefore, that future pharmacokinetic and clinical studies of new drugs 
should recognize the potential effect of sex; a fact that should be considered in 
protocols during drug development and pre-registration. 
These pre-registration studies and randomized clinical trials do provide indicators of 
adverse events. However, such studies are not designed to detect aIl possible adverse 
events that may occur [9]. Furthermore, in a "real-life" setting, many marketed drugs 
are prescribed to patients with characteristics that were not studied, or to those with 
co-morbid illnesses that were excluded from pivotaI trials. During the development 
phase of a drug, if no clinically significant gender-specific, treatment-related adverse 
events are observed, no cautionary statements would appear in the product labeling, a 
key document providing guidance to health care professionals. However, absence of 
such adverse events during clinical trials is not indicative of safety. It is known that 
clinical trials are not appropriate to detect rare events or those events with a long 
delay of onset [8, 9]. Gender differences may also not be detected in randomized 
controlled trials because conditions of drug utilization may be too homogeneous, and 
population size may be too restricted. 
investigate this sub-group. 
Studies are generally not powered to 
In this research project, a large post-marketing spontaneous reporting database was 
used in order to detect possible cardiac effects and gender influence that may not 
have been recognized during the clinical development of these macrolides (i.e. 
azithromycin and clarithromycin). In the past years, research has shown that the 
5 
quantitative analysis of spontaneous reporting data could enhance the detection of 
previously unrecognized safety issues [9]. Rence, the Adverse Event Reporting 
System (AERS) database (previously known as the Spontaneous Reporting System 
database) maintained by the United States Food and Drug Administration (FDA) has 
become the primary data resource for the study and identification of new and 
unexpected post- approval adverse drug events in the United States [9]. This 
database was used for this research project and was available through Pfizer Inc. at no 
co st. 
Data collected by the FDA, from suspected drug-related adverse event reports and 
other electronic medical information could aid these health authorities in identifying 
"signaIs" of adverse events and the patterns in which they occur. The more effective 
the tools health authorities can use to detect such patterns, the faster it can act to 
evaluate and act on these reports as appropriate [9, 10]. Effective automated methods 
that facilitates detection of ADRs, might allow the authorities to identify a pattern of 
adverse events in a specific population of patients taking a drug, or in patients who 
take a certain combination of drugs, and the agency could then communicate this 
knowledge sooner to medical professionals and patients - preventing more adverse 
events [9]. Identification of sub-populations at risk may lead to change in the product 
labeling (e.g. contraindications). It is interesting to note that, there have been 121 
product withdrawals in Canada, aIl for safety reasons, and aIl detected through the 
pharmacovigilance system, with the majority being the result of the spontaneous 
reporting database. 
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It is to be c1early noted that when a signal or hypotheses is detennined by a study of 
this nature, further detailed analysis by other methods may be necessary in order to 
detennine the real strength of the relationship and as a result, modifications to the 
product labeling may be considered [10]. The types of product infonnation change 
may require the addition of new risk infonnation to the sections covering ADRs, 
wamings, or precautions. As with any changes, the new infonnation should be 
placed and worded so as to maximize understanding by health professionals apd 
provide the most accurate prescribing infonnation in order to ensure patient safety. 
In today's environment, with recent product recalls (Bextra®, Vioxx®, Baycol®), it is 
expected that Health authorities worldwide will continue to monitor the marketplace 
to ensure that marketed products are labeled accurately and that critical product 
infonnation from the "real life" setting is discussed and provided to health care 
professionals. Agencies will improve the utility of effective automated methods that 
facilitates the detection of ADRs and develop new and innovative ways for extracting 
infonnation related to drug safety and risk assessment. Application of improved 
automated methods has the potential for even earlier detection of safety signaIs 
associated with marketed products [10]. Development ofthese tools holds promise as 
a way to optimize limited resources with the Health authorities and improve the level 
of consistency in their safety reviews [10]. This allows agencies to use the best 
science and the latest technology available to improve risk management of marketed 
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products. Specifically, through the use of effective automated detection methods, we 
can improve upon the current ability to understand adverse event patterns in pre-
market safety databases and assess subgroup differences (e.g. gender) related to 
safety [10]. 
The product information provided to health care professionals, for both 
c1arithromycin and azithromycin, indicates the' potential risk of cardiac events 
inc1uding developing cardiac arrhythmia and torsades de pointes (TdP), however, no 
gender effect is noted. This research may warrant the addition of new information so 
as to maximize the level of understanding by health professionals and provide more 
accurate product information in order to ensure patient safety, in particular, in more 
vulnerable patient subgroups, su ch as female gender. 
Continued investigation in the risk of serious adverse events such as cardiac effects, 
in particular with gender association, in commonly used drugs (e.g. antibiotics), is 
imperative and still remains an area in need of study. The use of a large 
postmarketing database and signal detection methods (proportional reporting ratios) 
are a useful way to keep track of new drugs as the y expand into real-world use [9]. 
This epidemiological model will investigate the effect of a potential effect modifier 
(i.e. gender) not discovered during clinical trials and perhaps may be used as a 
predictor of functional and pharmacologic differences between men and women. 
Understanding the potential mechanisms responsible for the greater risk of cardiac 
events (e.g. drug-induced arrhythmias) in women could lead to screening methods for 
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identification of individuals at risk for drug-induced cardiac events (e.g. arrhythmias) 
or to the development of drugs with reduced risk of inducing cardiacevents (Le. 
arrhythmias ). 
Ultimately, in this research, the goal is to provide safer and more effective treatments 
with more accurate prescribing information for health care professionals and for al! 
patients. In today's environment, health authorities, industry and institutions, in a 
joint collaboration, should continue to monitor the marketplace and work together to 
improve the risk management of marketed medicines 
2. Literature Review 
2.1 Adverse Reactions and the Cardiovascular System 
Adverse reactions reported for a product, including clarithromycin and azithromycin, 
may occur under normal use conditions of the product. Reactions may range from 
minor reactions like a skin rash to serious and life-threatening events such as a heart 
attack or liver damage. Adverse reactions are "undesirable effects to health products 
which include drugs, medical devices and natural health products" [l1J. Among a11 
potential adverse effects, a serious adverse reaction is defined "as a noxious and 
unintended response to a drug, which occurs at any dose and requires in-patient 
hospitalization or prolongation of existing hospitalization, causes congenital 
malformation, results in persistent or significant disability or incapacity, is life-
threatening or results in death" (11 J. 
Serious reactions have al ways been the most studied as their consequences can be 
dramatic. Most, if not aIl drug withdrawals that occurred in the past 30 years were 
motivated by the occurrence of such serious adverse drug reactions. Adverse effects 
related to the cardiovascular system can a11 be considered as potentially serious. They 
are systematically carefully studied and monitored in preclinical and early clinical 
studies, but as their frequency can be relatively low, sorne can only be detected after 
marketing and large exposure in the population. Almost a11 signaIs that have been 
triggered for blackbox wamings or withdrawals concemed cardiovascular effects. 
lO 
One can cite for instance, terfenadine and prolongated QT-syndrome, COX II 
inhibitors and myocardial infarction, pergolide and valvular fibrosis or anthracyclines 
and heart failure [6, 12, 13, 14, 15, 16, 17, 18]. Arrhythmias and life-threatening 
arrhythmias motivate much of the research in pharmacology, either for 
pharmacovigilance and therapeutic risk management or fundamental pharmacology 
and pharmacogenetics in an attempt to identify subgroups at particular risk. Torsades 
de pointes, and its predisposing condition QT prolongation have been widely studied 
and can be considered as one of the most dangerous, in particular for antiarrhythmics, 
antipsychotics and antimicrobials [18, 19, 20]. Among others, macrolides have been 
associated with an increased risk of QT prolongation. 
2.2 Effeet of Gender on Pharmaeokineties/Pharmaeodynamies and 
Cardiovaseular Effeets 
Identifying factors which may predispose the occurrence of adverse drug reactions is 
necessary to manage the risk. Known risk factors include increasing age, 
polypharmacy, liver and renal disease as weIl as gender. Female patients have a 1.5 
to 1.7 fold greater increase of developing an adverse drug reaction compared to males 
[21]. Women generally have lower lean body mass, a reduced hepatic clearance, 
have differences in activity of cytochrome P450 (CYP) enzymes (40% increase in 
CYP3A4, varied decrease in CYP2D6, CYP2C19 and CYP1A2), and metabolize 
drugs at different rates compared with men [22]. CYP3A4 is probably the most 
important enzyme associated with drug metabolism accounting for, perhaps, 50% of 
metabolism of therapeutic drugs [23]. Examples of increased CYP3A4 activity 
Il 
include erythromycin which is metabolized 25% more rapidly in women Il]. This 
may be explained by a gender difference in steroid hormones influencing CYP3A4 
activity (e.g. estrogen and progesterone), which may act as competitive inhibitors. 
Other important factors include conjugation, absorption, protein binding and renal 
elimination, which may aIl have sorne gender-based differences. The effect of gender 
on pharmacodynamies, however, is not clear and how these differences result in an 
increased risk of ADRs is also not clear [21]. The focus of this research is 
cardiovascular related adverse reactions, in particular due to its seriousness, and the 
influence of gender. 
Several clinical and experimental studies have also explored, ln particular, 
cardiovascular risk 'and gender, which suggests profound intrinsic differences of 
cardiac sensitivity [23, 24]. Particularly notable examples (and clinically relevant 
given its serious outcome) is the predominance of ADRs in women in response to 
drugs prolonging cardiac repolarisation or the QT interval, and particularly in the risk 
of developing drug induced torsades de pointes (TdP), a potentially fatal polymorphie 
ventricular tachyarrhythmia. These ADRs are not necessarily reported as torsades de 
pointes (TdP), however, may also present clinically as syncope, fainting, dizziness, 
palpitations, ventricular tachycardia or sudden death [24]. Macrolides, pentamidine 
and certain antimalarials were traditionally known to cause QT -interval prolongation, 
and now azole antifungals, fluoroquinolines and ketolides can be added to the list. 
Over time, advances in preclinical testing methods for QT -interval prolongation and 
better understanding of its sequelae, most notably torsades de pointes (TdP), have 
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occurred [25, 26, 27, 28, 29]. This, combined with the fact that several drugs have 
been removed from the market over the last several years, in part because of QT-
prolongation-related toxicity, has elevated the urgency surrounding early detection 
and characterization methods for evaluating non-antiarrhythmic drug classes, in 
particular, for certain susceptible sub-groups. The focus of this research will be the 
drug class of macrolides. 
In vanous studies reviewed, usmg data such as literature reVlews, clinical trial 
information databases and spontaneous reporting databases, cardiac events may be 
provoked by a limited number of drugs including macrolide antibiotics such as 
erythromycin. 
A review of the literature reveals that a much higher percentage of women than men 
develop Torsades de Pointes (TdP) arrhythmias after taking a variety of drugs, such 
as antihistamines (terfenadine, astemizole), antibiotics (erythromycin), antimalarials 
(halofantrine), antiarrhythmics (quinidine, d-sotalol), and miscellaneous other drugs 
[28, 29]. AlI of these drugs have in common the ability to block potassium channels, 
thereby prolonging cardiac repolarization and the QT interval on the ECG. The 
available experimental data support the hypothesis that gender differences in specifie 
cardiac ion current densities are responsible, at least in part, for the greater 
susceptibility of females for developing TdP arrhythmias. 
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Studies have shown that macrolides prolonging QT interval inhibit the rapid 
component of the delayed rectifier K+ CUITent (hr) through the block of K+ channels 
encoded by the human ether-a-go-go-related gene (HERG) [4, 30]. Reducing the 
repolarising of K + CUITents and prolonging the QT interval can be seen on the 
electrocardiogram. Drug induced disruption of cellular repolarisation underlies ECG 
abnormalities that are diagnostic indicators of aIThythmia susceptibility [28]. 
Published literature, although more limited, has also supported effects on cardiac 
repolarisation for c1arithromycin and azithromycin. 
2.3 Pharmacovigilance 
The principal objective of pharmacovigilance is the detection of adverse events 
related to the use of medicines that are unknown or novel in terms of their c1inical 
nature, severity or frequency. This entails the search for preliminary signaIs of such 
events. In the context of spontaneous reports the WHO (World Health Organization) 
de fines a signal as 'reported information on a possible causal relationship between an 
adverse event a drug, the relationship being unknown or incompletely documented 
previously. Usually more than a single report is required to detect a signal, 
depending on the seriousness of the event and the quality of the information. A 
single, weIl documented report with a positive re-challenge could represent a signal, 
although replication of findings in a series of reports is more often required. A signal 
does not establish that drug and event are causally related but suggests that further 
investigation may be waITanted to c1arify the observed association. 
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2.3.1 Advantages 
The goal of the FDA phannacovigilance system is to collect and assess suspected 
adverse drug reaction reports for products and monitor the safety profile of marketed 
health products to ensure that benefits of the products continue to outweigh the risks. 
The major advantage of the FDA's pharmacovigilance system lies in its ability to 
identify and characterize adverse events as they occur across the range and extent of 
medical practice. Although drugs undergo extensive testing before they are 
marketèd, pre-marketing clinical trials are inherently limited in nature. They are 
necessarily conducted with limited numbers of patients and are unlikely to identify 
rare adverse events. If the chance of an ADE is one in 10 000 patients exposed to the 
drug, there is a 9.5% probability of observing that ADE at least once in a clinical trial 
of 1000 patients [31]. Similarly, if an adverse event is not observed in a IOOO-patient 
clinical trial, the upper 95% confidence interval for the true rate of occurrence is three 
per 1000 patients [31]. 
After a drug is marketed, it will almost al ways be used in a broader and more varied 
patient population than the patient groups studied in the clinical trials. This has been 
characterized as the difference between the "average" patient and the "ideal" patient 
[32]. Drug effects in certain susceptible subgroups of the population, such as female 
patients, may not have been assessed in pre-marketing studies. Post-marketing drug 
use is also more likely to occur in patients with other concurrent disease conditions 
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and more complex medical therapies that could make them more susceptible to ADRs 
and drug interactions. 
Because of its Slze and breadth of potential data sources, the FDA's 
pharmacovigilance system serves as a warning mechanism to signal the existence of 
adverse events that were not detected in clinical trials. In most instances, it is the 
only signaling method available for newly marketed products. With alternative 
methods, su ch as formaI post-marketing surveillance studies there is often a 
significant time lag between the date a drug is first marketed and the point at which 
the database contains sufficient exposed patients to be able to assess more than the 
most common ADRs [31]. 
The FDA pharmacovigilance system has other advantages relative to alternative 
methods of postmarketing surveillance. It is sometimes the only available means for 
studying very rare ADRs, particularly unusual adverse reactions to infrequently used 
drugs. In such situations, the ADR reporting system can provide valuable 
information for case-series studies that often is not available from other sources [32]. 
ADR reports often contain a wealth of clinically relevant information that can be used 
to identify patient groups that are particularly susceptible to a given adverse event 
and conditions un der which adverse events are most likely to occur. 
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The FDA phannacovigilance system is inexpensive relative to other post-marketing 
surveillance systems, particularly considering the fact that it covers aIl marketed 
drugs, aIl geographic locations of the US and aIl medical settings. The system and its 
associated software allow FDA to obtain quick answers to drug safety questions. 
However, these answers are generally of the "quick and dirty" variety and need 
considerable refinement through additional analysis and review. With very rare 
exceptions, even the most sophisticated analysis of ADR reports cannot be considered 
definitive. These exceptions would include those instances in which a cluster of 
unique events that are temporarily associated with a drug exposure in the absence of 
significant confounders [31]. The primary strength of the ADR reporting system is 
its ability to signal potential problems and generate hypothesis. Other post marketing 
surveillance methods become more useful at this point as the need arises for testing 
hypothesis and quantifying risk. 
2.3.2 Limitations 
Although phannacovigilance databases do represent an extensive amount of 
infonnation there are important limitations associated with their use [31, 32]. These 
limitations make it difficult to quantify or compare risk associated with drug use. 
One of the most important limitations is underreporting (it is estimated that <10% of 
ADRs are reported). Cases of adverse events reported spontaneously to any 
surveillance pro gram which are referred to as the numerator of the incidence estimate, 
generally represent only a small portion of the number that actually occurred. The 
magnitude of underreporting remains a priori unknown and can differ across drugs of 
17 
comparison [31, 33, 34]. Furthermore, reported cases may not be representative of aIl 
cases with respect to severity and other characteristics. Information submitted in the 
reports is often inadequate in spite of attempts to follow up with initial reporters. 
This incompleteness in reporting often does not permit an adequate causality 
assessment for a case or series of cases that can be validated independently. 
Unlike clinical trial data, which are obtained under strictly controlled conditions, 
spontaneously reported information is uncontrolled and subject to the influence of 
biases. These biases are consequences of: the length of time a product has been on 
the market, effects of the media, country-reporting requirements, lack of motivation, 
time constraints for reporters, failure to diagnose the event or to attribute to drug use 
and quality of the data [32, 35, 36]. Reporting may be stimulated by a drug registry, 
resulting in an increased reporting rate relative to other drugs. The peak of 
spontaneous ADR reporting for a drug is at the end of second year of marketing, with 
a subsequent decline in reporting despite a lack of apparent decline in usage or 
change in ADR incidence [35]. Because of this, it is difficult to estimate the true 
incidence of adverse event associated with drug use. 
Compounding these numerator limitations is the lack of accurate denominator data, 
such as the population of users (number and characteristics), and drug exposure 
patterns [32]. The number of patients who took the drug is not known. A myriad of 
issues, such as noncompliance, abuse, incorrect use, and sporadic use can generate 
unreliable exposure estimates. Drug exposure data and background rates of events 
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for a particular population experiencing adverse drug events are difficult to obtain or 
are nonexistent. This information can be estimated from various sources such as: 
market surveys based on sales or prescription data, third-party payers or health 
maintenance organizations, institutional/ambulatory settings, or specifie 
pharmacoepidemiologic studies. Such estimations depend on the fact that patterns of 
use are known and are limited by factors su ch as stocking by pharmacies (which leads 
to an over-estimation ofthe denominator). 
Care must be taken in interpreting results from studies using these databases [31, 32, 
35]. Drug prescribing does not necessarily equal drug usage, and results derived 
from a specifie population (i.e. Medicaid recipients) are not necessarily applicable to 
the population at large. Numerator and denominator limitations make incidence rates 
computed from spontaneously reported data problematic. It is unusual in practice to 
know such variables as the number of reported cases, the total number of cases, the 
actual size of the exposed population (i.e. the number of treated persons or the 
number ofperson-time). Only gross estimates can be obtained. 
It is also known that the submission of a spontaneous report does not necessarily 
constitute an admission that the drug caused the adverse event [31, 32]. The causal 
relationship between the drug exposure and the adverse event reported to the FDA is 
not routinely evaluated for the vast majority of ADR reports. Elements such as 
temporal relationship between confounding factors such as concomitant drugs and 
underlying disease are assessed only for reports of specifie ADRs that are being 
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closely monitored. Other countries, such as France, do conduct imputability 
assessment on aIl reports received [31]. 
Although exploring signaIs in the FDA database based on clinical judgment in 
combination with threshold reporting frequencies 1S essentiaI, it may not aIw,~ys be 
optimal in systematically and rapidly detecting rare signaIs or signaIs obscured by the 
use of multiple drugs [31]. In assessing the safety of a drug in general use, how do 
we systematically separate the effects of a drug or multiple drugs from the 
progression of a disease or multiple concomitant diseases. We often do not have 
specific markers for drug toxicity clinical findings that can separate an inherent 
disease process from the unknown adverse effects of a drug or concomitant drugs. 
This task is easier if drug levels have been established that can separate therapeutic 
and toxic ranges [31]. However, for most marketed drugs, practical tests to identify 
toxic drug or metabolite levels are not widely used. It is imperative, however, that 
once a signal or hypothesis is detected using à spontaneous database, additional 
studies need to be done to confirm a true pharmacodynamic or pharmacokinetic 
interaction and to determine the strength of this association in daily practice. 
2.3.3 OtherPharmacovigilance Frameworks 
In order to identify a signal or determine the strength of a hypothesis, 
pharmacovigilance in Canada can also be carried out using other pharmacovigilance 
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databases/frameworks and drug management systems. Frameworks may use many 
types of information, for example; 
1) Drug regulatory authority frameworks [e.g. Canadian Adverse Drug 
Reaction Monitoring Program (CADRNIP), US FDA Spontaneous Reporting 
System] 
2) Drug manufacturer frameworks (e.g. patient registries) 
3) Clinicianlclinical groupldisease collaborative frameworks (e.g. BC Centre of 
Excellence for HIV / AIDS [37]. 
There is no c1ear consensus on the best way to carry out pharmacovigilance in 
Canada. Each of the above has their own unique strengths and limitations. In 
general, where population-level data and relatively open access for others to validate 
research conclusions are readily available (e.g. FDA database and the provincial 
formulary drug plans), resources for assessment are more limited. Wheie more 
focused resources are available (e.g. manufacturer registries and single-disease 
centres), data are more limited and opportunities for replication by others more 
restricted. Neither of the situations is ideal. Choosing the appropriate 
pharmacovigilance strategy is dependent on the nature of the research question, the 
availability of data sources, the required timeHne for results and availability of 
expertise to carry out the research [37]. 
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2.3.3.1 Drug Regulatory Authority Frameworks 
The drug regulatory authority frameworks e.g. FDA database, and the chosen 
database for this research, provide a well-known and established framework for 
submitting reports of adverse drug reactions, but is restricted by the voluntary nature 
of reporting, the incomplete information often contained in reports, poor quality data, 
the difficulty demonstrating a causal relationship between exposure and an adverse 
event and severe underreporting. It is estimated that only 10% of aIl adverse drug 
reactions (ADRs) are reported; the framework cannot be used to calculate incidence 
rates of ADRs. Post-market surveillance to evaluate drug safety and effectiveness 
has traditionally relied on spontaneous ADR reports in the post-market phase and 
remains the most highly used method for the first line surveillance of marketed drugs. 
It serves to detect previously unrecognized adverse events (in particular serious 
adverse events) associated with the use ofmedicines [37]. 
2.3.3.2 Drug Manufacturer Frameworks 
Drug Manufacturer frameworks (e.g. patient registries) provide additional 
information about patients who receive specific drugs but suffer from the problems of 
aIl observational trials; there is no randomized control group to provide comparison 
for drug effectiveness determination. Registries mandate reporting of very specific 
outcomes for aIl patients on a drug. They are not, however, often sufficient to 
de termine effectiveness or safety from the population perspective. 
22 
2.3.3.3 ClinicallClinical Group/Disease Collaborative Frameworks 
Clinicallclinical group/disease collaborative frameworks vary widely in their 
mandates, funding and research agendas. Chronic disease management projects focus 
on patients with a common disease and are usually focused on clinical issues, su ch as 
continuity of care, rather than outcomes evaluation. Research-oriented groups are 
able to organize and support many randomized controlled trials, which are published 
in respected peer-reviewed joumals, while sorne centers (e.g. BC Center for 
Excellence for HIV/AIDS) carry out observational trials on a well-studied cohort of 
patients) [37]. 
It is unlikely that one model will suffice in the long term, no matter how elaborate. 
Integrated and informed use of whatever mix of models best addresses specifie issues 
is likely to provide the best information on drug safety and effectiveness. 
\ 
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2.4 Signal Detection 
A program of post-marketing surveillance of any new pharmacological entity should 
inc1ude a strong approach to pharmacovigilance coupled with a proactive program of 
more structured pharmacoepidemiological studies. The best way to handle a crisis 
that involves a safety signal is to have anticipated it and launched a proactive 
program of complementary epidemiological studies in advance of the emergence of a 
problem. Suggestions of possible troublesome adverse effects from animal studies or 
early clinical studies may warrant being attuned to this risk and building a system to 
monitor relatively large populations using epidemiological methods [38]. 
Since 1998, the US FDA has been exploring new automated and rapid data mining 
techniques [38, 39]. These techniques have been used to systematically screen the 
FDA's huge database of voluntary reports of adverse drug e~ents for possible events 
of concem. The large database of voluntary adverse event reports of the US FDA is 
the primary data resource for the study and -identification of adverse reactions to 
regulated drugs and biological products in the US. This database, discussed further in 
section 4.2, contains approximately 40 years of data and over 6 million reports across 
aIl marketed products in the US and increases in size each year by more than 300 000 
reports. These data have provided critical evidence about known and unknown harms 
associated with single or combination drug treatments [40]. 
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There are well-known inherent problems in systematically analyzing and interpreting 
voluntarily submitted data involving multiple drugs, medical conditions, and events 
per report, without the benefit of a research protocol, randomization, and a control 
group of persons not taking the drug. As mentioned, other difficulties include 
chronic underreporting, occasional publicity-driven and litigation-driven episodes of 
over-reporting and misreporting, incomplete and missing information, and 
inconsistencies and changes over time in reporting and naminglcoding practices. In 
addition, there is considerable uncertainty regarding the quality and completeness of 
the information contained in each data field, including dosage, formulation type, 
timing of exposure, and length of exposure and follow-up and in estimating the 
corresponding product exposure and background rate of adverse events. The 
extraction of useful information from this database presents multiple challenges, 
inc1uding managing, storing, and analyzing such a large amount of data, and 
resolving event and drug dictionary problems and data miscoding [41]. 
There is a need for analytical methods that are capable of systematically screening 
this database to identify potential serious adverse events of concern in such a noisy 
background that properly balance the concerns for excessive signaling and accounting 
for background noise. "SignaIs" from a spontaneous reporting system can be 
detected by a systematic review of aIl reports that are received within a certain period 
of time by experts in this field. With the increasing number of reports, there is a 
growing need for a computerized system that facilitates detection of adverse drug 
events. Attempts have been made to develop alert processes for such databases, and 
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more recently sorne authors have used a similar approach when analyzing data [41, 
42,43). 
2.4.1 Signal Detection Methods 
Since other sources of data can also supply signaIs, a more general definition is 'an 
alert from any available source that a drug may be associated with a previously 
unrecognized hazard or that a known hazard may be quantitatively (more frequent) or 
qualitatively (e.g. more serious) different from existing expectations [43]. Provided 
is a comparison of commonly used signaling methods for post-marketing drug safety 
surveillance: Proportional Reporting Ration, the Bayesian Confidence Propagation 
Neural Network and empirical Bayes screening. Each method will be reviewed along 
with its strengths and limitations [38,39). 
Different signal detection methods have different data requirements. Spontaneous 
reporting systems constitute the major source of data for this activity but drug 
utilizationlsales estimates and/or observational epidemiological data may be required 
according to the method used. 
The simplest methods of signal detection involve periodic review of crude frequency 
data by expert human analysis. Within-drug and between-drug crude numerical 
comparisons of reporting frequency or time trends are made. An example is the 
former two threshold signaling method used by the WHO Programme for 
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International Drug Monitoring. Suspect drug-event combinations reported at least 
twice (level 2) or five times (level 5) were sent to expert reviewers for selection of 
possible signaIs. Drawbacks inc1ude the usual limitations and biases of voluntarily 
reporting systems such as underreporting, lack of exposure measurements, 
incomplete data, the considerable human prejudgement involved and underutilization 
of data, since signaIs for a given drug are sought using only data for that drug [44]. 
Several statistical methods have previously been suggested for surveillance activities 
inc1uding postmarketing safety surveillance. Methods inc1ude proportional reporting 
ratios (PRRs) or case/non-case design (method used in this research project) and 
Bayesian data mining [45]. 
2.4.2 PRRs or CaselNon-Case Design 
PRRs are based on the observation that the proportional frequency of individual 
adverse reactions reported is relatively constant over time despite the significant 
increase in total repot;ts. PRRs can be understood by the fol1owing 2X2 contingency 
table and equation: 
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Table 1. 2X2 Table for the Proportional Reporting Ratio Calculation 
Specifie Drug Ali other drugs 
Specifie Adverse Event A B 
Ali other Adverse Events C D 
PRR = [a/(a+c)]/[b/(b+d)] 
Drilg-event combinations with at least three reports, a PRR > 3 and a chi-square >5 
would represent a signal. PRRs are relatively easy to understand and calculate and 
are now part of routine surveillance activities. Computational ease of use is an 
important advantage considering the dynamic nature of the data and associated 
sequential scans of increasingly large data sets. Its greatest use may be in 
highlighting drug-event combinations with intermediate PRRs, since those with very 
large scores were noted to involve recognized adverse events, while pairs with PRRs 
near 1 may be triaged as likely background noise. Care must be taken when strong 
signaIs are detected for a given drug, since this will reduce the PRR for other adverse 
events with that drug. This could be addressed by exc1uding events with very strong 
signaIs [46]. 
The proportional reporting ratios (PRRs) or case/non-case method has been designed 
to determine whether an adverse event pccurs more frequently among patients treated 
with the drug of interest than among patients treated with other drugs and presenting 
other ADRs. In "c1assical" epidemiology, the comparator is the occurrence of the 
adverse event under no exposure. The particularity of the case/non-case method is 
that, by definition, aIl patients in the comparator group are exposed to a drug and they 
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aIl have experienced another adverse event (otherwise they would not appear in the 
spontaneous reporting database). One therefore has to assume that exposure to other 
drugs is equivalent to no exposure to the drug of interest in terms of risk of the 
adverse event. Contîngency tables can be constructed and subsequently 
disproportional drug-ADR combinations are identified, and used for the detection of 
signaIs [45, 47, 48]. The association between the drug and adverse event of interest is 
quantified by the ADE reporting odds ratio, which îs an estimate of the relative risk 
(RR). 
2.4.3 Bayesian Data Mining 
Bayesian data mining is a second method and a major initiative in signal detection. 
Data mining integrates several technologies and knowledge domains, inc1udîng data 
management, probability and statistics, machine learning, and data visualization, to 
detect novel and potentially useful patterns in large databases in the absence of a 
priori hypothesis. Each Bayesian method seeks to take advantage of the vast amount 
of information on drugs and adverse events contained in the entire database. There 
are two different Bayesian mining techniques. One method used ideas derived from 
information theory to calculate a quantity known as the information component (lC) 
for each drug-event combination in the database. The other method involves a data-
mining technique known as Empirical Bayes Screening (EBS). It ranks drug-event 
combinations according to how large the number of reports of that drug-event 
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combination is compared with what would be expected if the drug and event were 
statistically independent [49]. 
The first automated signal-generation system is based on a Bayesian Confidence 
Propagation Neural Network (BCPNN) (developed by the WHO). It lS a 
methodology which uses a statistical approach to generate safety signaIs. This 
automated procedure finds signaIs with known probability di fference from 
background data [49]. Its neural network approach measures dependencies between 
drugs and adverse reactions within the ADR database. Dependencies are established 
by using a measure of disproportionality called the Information Component (IC). It is 
the measure of strength of the association between specific drug and reaction when 
both are present in a report. The more cases that are reported, the more accurate the 
estimation will be. As with spontaneous reporting of ADRs, limitations apply for the 
use the neural network system. IC values reflect only statistical correlations and do 
give absolute certainty about causality. There is also no comparison data to support 
the advantage of this method, in particular comparisons with other statistical 
techniques. In a comparison with previous signaling approaches using manual review 
of more frequent ADR reports of new drugs, signal detection efficiency of the method 
was far from being optimal, and clinical judgment is still required to define a possible 
signal. Furthermore, it may result in a very large number of signaIs which must be 
investigated a posteriori [50, 51]. 
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Another approach initially developed and applied to the FDA database of 
spontaneous reports is Empirical Bayes Screening (EBS). It enables the screening 
and analysis of a large database of adverse event reports that is fast and efficient, 
enabling the evaluation of aIl drugs and ADRs of the database, or of selected 
portions. The approach is that of a large, two-dimensional frequency count table with 
many rows and columns. Every report is cross-classified according to the drug(s) and 
ADR(s) to obtain data frequency counts on drug-ADR combinations. _ The total 
frequency counts of the database are used to compute a baseline model and to 
calculate expected baseline counts for each cell under the model. Further modeling is 
then applied to the ratios of expected and observed counts. A Bayesian estimation 
strategy and the scores associated with such estimates are then used to identify those 
cells that highly deviate from the expected "null" model [51]. 
PRRs, BCPNN and EBS are currently the most widely studied and used methods of 
automated signal detection. Computational intensity varies with each model and the 
question naturally arises as to which is the preferred method for a given database. 
Many performance characteristics must be considered, including the total number of 
signaIs detected and the proportion that are meaningful. In almost aIl instances these 
methods of automated signal detection have been applied to post approval safety 
databases that are global in extent and contain hundreds of thousands to millions of 
adverse event reports [51]. In this research project the PRR or case/non-case method 
was most appropriate and the preferred method. PRRs are relatively easy to 
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understand and calculate, an important advantage, and are now ,part of routine 
surveillance activities, so this method has increasing evidentiary support. 
2.4.4 The Signal and Subsequent Actions 
lt is important that the actions taken following a signal are appropriate and· 
proportionate to the strength of the signal. If the infonnation confinns a likely 
relationship to the drug, the next appropriate actions may inc1ude; 
- Creating a special questionnaire or fonn for collecting additional infonnation on an 
ongoing basis 
- Adding further investigations to subsequent c1inical trials 
- Setting up a special clinical trial or epidemiological study to help solve the problem 
(e.g. fonnal epidemiologic observational studies, post-market randomized clinical 
trials (RCTs) or large sample trials). 
- Setting up panel of experts from within and without the company to debate the 
problem 
- Adding the AE to the product labeling 
As the signal is strengthened (or weakened) by each successive action, another action 
(or inaction) becomes appropriate. The appropriate action will be a matter of 
judgment when aIl available infonnation has been collected. 
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2.5 Overall Conclusion from the Literature Review 
What is missing in terms of evidence? Post-marketing analyses have not yet 
indicated any potential influence of azithromycin or c1arithromycin on specific 
adverse events (such as cardiac events) in particular more likely provoked by the 
female gender and product labeling does not indicate the risk. The objective ofthis 
research project was to assess, through the FDA spontaneous reporting database, the 
association between azithromycin and c1arithromycin and the reporting of cardiac 
events and to determine whether the association is modified by gender. 
The product information provided to health care professionals, for both 
c1arithromycin and azithromycin, indicates the potential risk of cardiac events 
inc1uding developing cardiac arrhythmia and torsades de pointes (TdP), however, no 
gender effect is noted. As a subsequent action, this research may warrant the addition 
ofnew information so as to maximize the level ofunderstanding by health 
professionals and provide more accurate product information in order to ensure 
patient safety, in particular, in more vulnerable patient subgroups, su ch as female 
gender. 
Due to its size and breadth of potential data ·sources, the FDA pharmacovigilance 
database was the database of choice within this research. The FDA database was 
available through Pfizer Inc. at no cost. It functions as a waming system for adverse 
events not detected during pre-approval testing. It contains adverse event reports 
/ 
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with approved drugs submitted in accordance with mandatory reporting obligations 
by pharmaceutical companies and voluntarily by . health care professionals and 
consumers. The FDA database provides "quick" answers but requires refinement 
through additional analysis and review. The proportional reporting ratios (PRRs) or 
case/non-case method was the most appropriate method and therefore used to screen 
the database to potentially detect any signaIs of concem. Following data analysis and 
as will be determined, other postmarketing surveillance methods may become more 
useful for testing hypotheses and quantifying risk. 
3. Specifie Study Objectives 
• To assess the association between azithromycin and clarithromycin, and the 
reporting of cardiac events; 
• To determine wh ether this association is modified by gender (i.e. does it differ 
between men and women?) 
• To determine whether differences observed across genders can by attributed to 
differences in patterns of drug use (i.e., duration, dosage) or patient characteristics 
such as medical history. 
4. Methods 
4.1 Overview of the Design 
In this researéh project, a large post-marketing spontaneous reporting database, 
maintained by the United States Food and Drug Administration (FDA), was used. 
Healthcare professionals, drug manufacturers and consumers send reports to the FDA 
by means of a limited number of questions on a special report form pertaining to the 
patient and the suspected ADR(s). After being received by the FDA, information such 
as the ADR(s) is coded and fi1ed within the FDA database and can subsequent1y be 
used for further evaluation and analysis of the data. 
ln this database, the unit of analysis was the spontaneous report. In the time period 
covered in this study (1992-1997), the FDA spontaneous reporting system (SRS) was 
used, which was in effect from 1969 to August 1998. In November 1997, the US 
FDA proceeded to change thecomputerized database to the Adverse Event Reporting 
System (AERS) [35] and the new ADR coding system (COSTART Co ding Symbols 
for a Thesaurus of Adverse Reaction Terms versus MEDRA Medical Dictionary for 
Regulatory Activities) was introduced. Hence, to avoid heterogeneity in data sources, 
only the period prior to the system change was retained. 
The case/non-case method was used to determine whether an adverse event (i.e. 
cardiac event) occurred more frequently among patients treated with the drug of 
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interest, i.e. clarithromycin or azithromycin, than among patients treated with other 
drugs and presenting other ADRs, and to investigate the effect of gender on this drug-
event association. We consider that the case/non-case method is a novel application 
of this design because it was used to investigate the effect of a potential effect 
modifier (i.e. gender) on a drug-event association, as opposed to the effect of the drug 
per se. 
In the event that a gender difference was indeed observed, it may have been 
interpreted either as a "true" effect modification of the risk by gender, or as a 
confounding effect due to differences between men and women in the patterns of use 
of these antibiotics or patient characteristics such as medical history. In order to 
detennine whether there may be such a confounding effect, a population-based 
utilization study was also conducted as a sub-study, using the Regie de l'assurance-
maladie du Quebec (RAMQ) database, under assumption that gender differences in 
patterns of drug use would besimilar to those found in the US, i.e. the population 
targeted by the FDA pharmacovigilance database. 
4.2 The Food and Drugs Administration (FDA) Spontaneous Reporting 
Database (SRS) 
The FDA receives spontaneous reports from a wide variety of sources, including 
phannaceutical manufacturers and health care professionals. Health èare 
professionals send reports to the FDA on a voluntary basis, however, phannaceutical 
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manufacturers are required to submit to the FDA, reports of aH suspected adverse 
events for their products. These reports may have reached the manufacturer from a 
variety of sources, including health care professionals, patients, clinical trials 
involving marketed drugs and the scientific literature. The reports may be domestic 
or foreign affiliates of the manufacturer. Currently, the actual reporting requirem,ents 
vary according to how long the drug has been marketed, the type of event 
(characterized in terms of seriousness and labeling status), and the source of the 
report (domestic, foreign, literature, or study) [35]. The manufacturer must also 
. report any serious unlabeled events to the FDA within 15 days after the time they 
become aware of such events. Fifteen day reports are also required when the 
manufacturer observes an increased frequency of a serious labeled event, above that 
which would be expected on the basis of increasing drug use. While the FDA may 
specifically request follow-up reports for ADRs that are being c10sely monitored, the 
great majority of follow-up reports are sent without FDA prompting, as 
manufacturers ob tain additional information. It is importa~t to note that the 1962 and 
1985 modifications to the Food, Drug and Cosmetic Act of 1938 established shared 
responsibilities between the pharmaceutical industry and the FDA. These regulations 
c1early require the manufacturer to systematically collect and review ADRs, triage 
these events according to unambiguous definitions related to seriousness and labeling 
expectations, and report ADRs at specified time intervals to the FDA as noted above. 
Within the FDA, these reports are then distributed to both the Division of 
Epidemiology and Surveillance (which processes, evaluates, and monitors them), and 
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to the medical review divisions, which have primary regulatory responsibility [31, 
35]. 
Reports received from manufacturers and health care professionals, account for 
approximately two-thirds of aIl reports in the FDA system [31]. Eight percent of aIl 
reports involved adverse events occurring in other countries. Consumers accounted 
for 23%, while study and literature reports represented only 1 % of the total. 
For each report, the information requested by the FDA regarding the adverse drug 
event includes: (1) patient information (i.e. gender, date of birth); (2) event 
information (i.e. description of the event including seriousness/severity, onset of 
symptoms, date of occurrence, outcome, and relevant medical history including 
diseases and factors possibly related to the event, laboratory findings); (3) medication 
information (suspected drug(s), dose, frequency, route of administration, concomitant 
medical products and date ofpast drug use); (4) initial reporter identity (which is kept 
confidential by the FDA); and (5) manufacturer-related information (name of drug 
manufacturer, date manufacturer received report) [31]. During the time period 
covered by this study (1992-1997), sorne information, as described above, was not 
obligatory and therefore not recorded. 
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4.2.1 Data Source 
Data received by the FDA between the years 1969 and 2004, consisting of various 
files, with infonnation on over 6 million ADRs, was obtained for this research. Using 
all of this data captured and received from the FDA phannacovigilance database, a 
working database was created. Extensive work was involved in the preparation and 
processing of the FDA database. 
To create the working database, the domain was restricted to all data reported in the 
FDA SRS specifying date of occurrence (i.e. not date of reporting) of the adverse 
event between the years 1992 to 1997 (see 4.2.2. Study Period). Data originating 
from the various files were linked through a report number which is unique for each 
adverse reaction that has been reported (detailed below). The resulting linked 
database consisted of a total of potential 2,460,894 reports specifying date of 
occurrence of the adverse event between 1992 and 1997, which included the 
following infonnation on each report; report number, age, sex, reaction infonnation 
(i.e. Costart tenn), case or control (i.e. cardiac event versus no cardiac event), drug 
name (i.e. clarithromycin [exposed] or azithromycin [exposed] versus other 
[ unexposed]). 
Note that in November 1997, the new ADR coding system, Medra, was introduced, 
and hence correspondence to the Costart classification, in codes and tenninology, was 
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also developed in order not to exclude any reports unnecessarily and create the 
working database. 
AU data captured in the FDA SRS was contained and received on CD-ROMs in the 
ASCII format. The information on the CD-ROMs was divided into parts: 1969-1985 
(CD-ROM 1&2), 1986-1992 (CD-ROM 3&4), 1993-1995 (CD-ROM 5&6), 1996-
1997/98 (CD-ROM 7, 8&9), 1999-2000 (CD-ROM 10), 2001-2002 (CD-ROM Il), 
2003-2004 (CD-ROM 12). 
The adverse reaction information was supplied in five files on each CD-ROM (4 files 
only were accessed for this study). The files retained for the study are listed below 
and the variables extracted from each file are described in the following paragraphs. 
Data originating from the various files were linked through the report number which 
is unique for each adverse reaction that has been reported. 
The following files were provided by the FDA and were used to create the working 
database: 
1. Demographie file: contained information on demographic characteristics for 
each patient, administrative information, and the initial report number. The 
variables retained for the study were the report number (FDA sequentially 
assigned number), age on the date of the report, sex, month/year of receipt of 
report. 
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2. Drug file: contained druglbiologic information on the drugs mentioned in the 
repo~s as the "suspected" drug. The variables retained for the study were 
report number, drug name, suspect status (described as 'suspect medication' or 
'other'), daily dosage (total dose in 24 hours), units of measure (i.e. g, mg 
etc.), route of administration (i.e. p.o., i.v.), start date of drug, stop date of 
drug. 
3. Adverse reaction file: describes the adverse effect that is reported using the 
CoStart Classification. The AE is coded from FDA's "Coding symbols for a 
thesaurus of standard adverse reaction terms [Costart]". The dictionary is 
categorized by levels, i.e. body system (e.g. Cardiovascular system), body sub 
system and preferred term. Finally, there are included terms and investigator 
terms which map to the preferred terms. The included terms are a part of the 
original dictionary as published by the FDA. The investigator terms are the 
terms received by investigators and mapped to the most appropriate preferred 
term. The preferred terms are mapped to a body sub system and body system. 
The severity of event is not described. The variables retained for the study 
were report number, Costart term (Table 2), reaction onset date. 
4. Source file: contained information on the source of the reports (i.e. health 
professional, consumer, literature, study, or foreign). The variables retained for 
the study were report number, report source. 
5. Comments file: contained comments/details on individual cases. Although 
there is a comments file, it was not created until 1994. Therefore, it was not 
retained for the study. 
42 
4.2.2 Study Period 
It is important to use a broad time period in order to maximize the number of reports, 
in particular inclusion of a period of peak reporting [52]. A greater number of 
reported cases will increase the precision of measures of association. The period 
selected, for which ADR reports were identified (i.e. date of occurrence of AB 
between J anuary 1, 1992 to December 31, 1997), included the second/third year 
which azithromycin and clarithromycin were marketed. ADR reporting is typical1y 
heaviest early in a product's life cycle. ADR reporting is five times greater in the 
second versus fifth marketing year [35]. Therefore, azithromycin and clarithromycin 
ADR reports should have been at its peak during this selected period. 
4.2.3 Eligibility criteria 
Using the working database consisting of a total of 2,460,894 reports, a further 
breakdown of reports from the working database was determined by the fol1owing 
inclusion and exclusion criteria; 
Inclusion Criteria 
• Reports specifying date of occurrence (i.e. not date of reporting) of the adverse 
event between January 1, 1992 and December 31,1997 
• Reports involving patients ~ 18 years of age 
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• Reports originating from health professionals only (physicians and pharmacists) 
to avoid misdiagnosis of cardiac effects. 
• Reports originating from individuals living in the D.S. only. 
Exclusion Criteria 
• Reports originating from a clinical trial setting. 
• Reports originating from consumers. 
'. Reports excluding information such as age, sex, drug name, reaction information, 
source of report, reaction onset date. 
4.2.4 Cohort Definition and Identification 
4.2.4.1 Case ascertainment 
From the reports meeting the above inclusion criteria and were retained within the 
study, the cases were defined as spontaneous reports of ADRs associated with the 
cardiovascular body system (using Costart terms) and the 'non-cases' consisted of aIl 
other reports. 
For cases, cardiac effects included; cardiovascular arrhythmias, such as ventricular 
fibrillation, torsades de pointes (TdP), cardiac arrest, tachycardia, bradycardia, 
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atrioventricular blocks, extrasystoles, QT interval prolongation, ECG abnorrnalities, 
and a combination of these terrns. To consider the cardiovascular system as a whole 
would have been problematic since sorne diagnoses were not applicable. For 
example, other forrns of he~rt disease such as occlusion of arteries and diseases of 
arteries, arterioles and capillaries such as atherosclerosis or aortic aneurysm were 
excluded from the study. Only events which could physiopathologically be associated 
with drugs were retained. The validity of the Costart terrns retained as cases was 
deterrnined by physician review. A listing of terrns that were retained as cases can be 
found in Table 2. The terrns were used to ID aIl potential cases. 
In the ADR report, the dictionary of terrns used for the adverse event has varied over 
time (i.e. Costart, Medra, WHO art, or reporter's terrn may have been used). Costart 
terrns were used during the time period covered by this study (1992-1997). Careful 
consideration was given to all events of the cardiovascular body system in order not 
to exclude any reports unnecessarily. Because of the large number of reports, 
imputability assessment was not conducted. 
4.2.4.2 Ascertainment ofnon-cases 
Non-cases were defined as spontaneous reports of ADRs other than events associated 
with the cardiovascular body system (i.e. reports involving aIl other ADRs) during 
the same study year. No matching was conducted on year or patient characteristics. 
Table 2. A Listing of COSTART Terms Retained as Cases 
COSTART Term 
Arrhythmia 
Atrial Arrhythmia 
Atrial fibrillation 
Atrial flutter 
Atrial septal defect 
Atrioventricular (Av) block 
Atrioventricular (A v) block 
complete 
Atrioventricular (Av) block first 
degree 
Atrioventricular (A v) block second 
degree 
Bigeminy 
Bradycardia 
Bundle branch block 
Cardiac Arrest 
Electrocardiogram (ECG) 
abnormallabnormalities 
Extrasystoles 
Heart arrest 
Heart block 
Nodal arrhythmia 
Nodal tachycardia 
Pr interval prolonged 
Pr interval shortened 
Qt interval prolonged 
Qt interval prolongation 
Qt interval shortened 
Sinus bradycardia 
St depressed 
St elevated 
Supraventricular extrasystoles 
Supraventricular tachycardia 
Syncope 
T amplitude decreased 
T inverted 
Torsades de pointes (TdP) 
Ventricular arrhythmia 
Ventricular extrasystoles 
Ventricular fibrillation 
Ventricular septal defect 
Ventricular tachycardia 
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4.2.5 Definition of Exposure 
Within the determined cases and non-cases, a further breakdown of reports was 
depicted by exposure to c1arithromycin, azithromycin or other drugs. The dependent 
variable of interest was the mention of c1arithromycin or azithromycin as the 
suspected medication involved in the reported adverse effect. The comparison group 
(i.e. unexposed) was the use of any other drugs as the suspected medication. 
4.2.6 Covariables 
Age and sex were considered as covariables, as both are considered as potential 
confounders. Both sex and age were required variables in order for report within 
FDA database to be retained. If information on either variable was missing, report 
was exc1uded. In aU individuals, pharmacology and pharmacokinetic activity change ( 
with time, therefore, age was an important factor for which to adjust. According to 
literature, female gender appears to be a risk factor for cardiac effects. 
Information su ch as body weight, history of cardiovascular problems (e.g. 
hypertension), smoking status were not available in the database during the time 
period covered in this study (1992-1997). Consequently, these could not be 
considered as potential confounders or risk modifiers. 
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4.2.7 Statistical Analysis 
According to the case/non-case design, the association between the two antibiotics 
and cardiac effect was quantified using the proportion reporting ratio (PRR) as an 
estimate of relative risk. In this study, macrolides (Le. azithromycin and 
c1arithromycin) were compared to aIl "other" drugs in the database with respect to the 
risk of occurrence of a cardiac event. NI and N2 subjects have been treated with 
macrolides and "other drugs", respectively, and followed during a given period of 
time during which K 1A and K2A cases of a cardiac event have been observed. The 
number of reports of "other" reports was large compared to the number of cardiac 
events, therefore the odds ratio was a valid estimate of the relative risk/PRR. 
Using this method, contingency tables were derived from the data, and the association 
between the use of clarithromycin or azithromycin and the reporting of cardiac events 
was quantified through the proportional reporting ratio (PRR) or relative reporting 
ratio (RRR). To assess the potential modifying effect of gender on this association 
we compared the PRRlRRR obtained for men with that for women. 
PRRs were calculated using the following 2X2 contingency table and calculation: 
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Table 3. Two by Two table used for the Calculation of the PRRs 
Specifie Drug AIl other drugs 
(i.e. clarithromyein/azithromycin) 
Specifie Adverse Event (i.e. A B 
eardiae event) 
AlI other Adverse Events C D 
(i.e. no eardiae event (other 
ADRs) 
PRR = [a/(a+c)]/[b/(b+d)] 
These statistics measure how much more frequently, the event is reported with the 
drug than with aIl other drugs. 
PRRs were based on the observations that the proportional frequency of the 
individual adverse reactions reported is relatively constant over time despite the 
significant increase in total reports. A PRR > 3 would represent a signal. 
In order to determine whether the strength of the association between the antibiotics 
and cardiac effects differed between men and women, gender was considered as an 
effect modifier. Renee, the contingency tables were stratified by gender, and a Chi 
Square test was used to compare the proportion of cardiac events in females versus 
males and adequately confirming a gender effect. Furthermore, an interaction term 
was included in a multivariate logistic regression model adjusting for age group. 
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4.3 Régie de l'Assurance-Maladie du Quebec (RAMQ) Database 
Using the Régie de l'assurance-maladie du Quebec (RAMQ), a population drug 
utilization study was conducted in the population of elderly users of Quebec (age 
65+) under the assumption that gender differences in patterns of use would be similar 
to those found in the U.S (Le. the population targeted by the FDA pharmacovigilance 
database. 
In order to investigate if the effect of gender in cardiac reporting rates could be 
confounded by patterns of drug use (i.e. to determine whether patterns of antibiotic 
use differed across gender in real-life setting), a cohort study was conducted 
according to various categories of antibiotic use (i.e. dosage, duration, co-morbidity 
and concomitant medications). Data was obtained from the RAMQ pharmaceutical 
services database. This database, created in 1975 in the context of a universal drug 
program for the elderly and the welfare recipients, includes information on aU out-
patient medications received by members of the plan. Until 1996, aU Quebec elderly 
were eligible. Since 1996, elderly have the opportunity to join private insurance 
programs but only 2.4% chose to do so. Y ounger age groups have been eligible to 
the public program since 1996 only if they cannot be covered by private insurance. 
Consequently, during the time period covered by this study (1996), prescription data 
were only available for the elderly population. This study period was chosen because 
it corresponded to the last study year retained for the main study. 
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4.3.1 Data Source 
In order assess patterns of drug use (i.e. dosage, duration of treatment) or patient 
characteristics su ch as medical history between males and females, the prescription 
database received from the RAMQ included the following information: 
• ID number 
• Date of dispensinglservice 
• AHF classification of medication (antibiotics, antihypertensive agents etc) 
(based on RAMQ book of reimbursed medication) - codes for cardiac drugs 
were identified 
• Denomination Code 
• Medication Code 
• Dosage form (tablet, capsule, suspension) 
• Dosage* 
• Duration oftreatment (days)* 
• Quantity of medication dispensed (number of tablets, capsules etc.)* 
* variables used to ca\culate patterns ofuse (i.e. Prescribed daily Dose = (Dose/unit X Quantity) divided by 
prescribed duration of treatment). 
Information pertaining to medical services received by the patients (from January 1, 
1995 to December 31,1997, inclusive) was provided as follows: 
• Control number 
• Date of service 
• Code of act (based on Canadian classification of Surgical & Medical Acts) -
codes for cardiac procedures/examinations were identified 
• Code of Diagnosis (based on IC9 classification) - codes for diagnoses 
pertaining to a cardiac class were identified 
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• Specialty of Professional (cardiologist, neurologist, etc) 
Demographie information was also provided (i.e. ID number, date of birth, date of 
death and sex). 
4.3.2 Study Period 
The study period from January 1,1996 to December 31, 1996, was chosen because it 
corresponded to the last study year retained for the main study. 
4.3.3 Cohort Definition and Identification 
A random sample of 4000 patients (66 years old and up) were selected for analysis 
(2000 patients having received azithromycin and 2000 having received 
c1arithromcyin). Note that patients having received both azithromycin and 
c1arithromycin between January 1, 1996 and December 31, 1996, were inc1uded with 
the population treated with the first drug prescribed (either c1arithromycin or 
azithromycin). First dispensing date in 1996 was retained as the index date. Patients 
were followed for a period of 1 year following the index date. 
This cohort study inc1uded new users (i.e. no prevlOus history of use of either 
antibiotic during the year prior to treatment initiation [1995]) of azithromycin and 
c1arithromycin as identified in the database from January 1, 1996 and December 31, 
1996. New use was defined as absence of dispensing for these medications in 1995. 
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4.3.4 Co variables 
Men and women were compared with respect to patterns of drug use (i.e. starting 
dose, duration of use) and patient characteristics such as medical history (i.e. 
dispensing(s) of cardiac medication, examination/procedure related to cardiology, 
diagnosis of cardiac condition). 
Patterns of drug usage were derived from the following data readily available in the 
database: date of dispensing/service, prescribed duration of treatment (days), quantity 
of medication dispensed, and dosage. Differences in the patterns of antibiotic use 
between male and female were determined using mean duration of use and mean 
dosages. 
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All medical servIces (medical examinations/procedures and diagnoses) during the 
year prior to index date were identified and provided in the RAMQ medical services 
database in order to assess patient medical history. Patient overall health status was 
assessed from dispensing(s) received during the year prior to the initiation of the 
antibiotic treatment, using the Chronic Disease Score [53]. History of cardiac 
conditions, inc1uding hypertension was determined though the dispensing of marker 
drugs. Cardiac events and procedures were identified in the medical services 
database. 
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Differences in the profile users were determined by comparing sex ratios, mean age, 
duration of use, starting dose and patient medical history (i.e. history of cardiac 
medication, examinationlprocedure related to cardiology and diagnosis of cardiac 
conditions ). 
4.3.5 Statistical Analyses 
Patterns ofuse were compared across men and women. Bivariate analyses were used 
to compare dosage. 
4.4 Ethical Considerations 
AlI data has been kept confidential and ID number was scrambled. The selection of 
cases and non-cases, as weIl as the application of the inclusion/exclusion criteria was 
conducted on-site at Pfizer. Only the variables required for the study, as specified in 
the sections above, were extracted and aIl ID numbers were scrambled. No contact 
with the patient, the ADE reporter, or additional chart review was conducted. Only 
grouped data was reported. Only anonymized data was transferred to the Faculty of 
Pharmacy. The project was submitted for approval to the University of Montreal 
Ethics Committee. 
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5. Results 
5.1 FDA Spontaneous Reporting Database 
5.1.1 Study Population 
Using aU data captured from the FDA spontaneous reporting database, a working 
database with a total 2,460,894 reports was retrieved (see 4.2.1). Of the potential 
total reports retrieved, only 248,230 reports met the eligibility criteria and were 
retained in the study [2,212,664 reports were excluded] (see 4.2.3). From the reports 
meeting the inclusion criteria, the cases and non-cases were defined (see 4.2.4). 
Figure 1 depicts the selected number of reports from the working database and 
breakdown of total reports. Figure 2 indicates reasons for exclusions and the 
corresponding number of reports. Exclusions of reports were observed in both the 
male and female population and were roughly similar in proportion. 
5.1.1.1 Numbers of Cases and non-cases 
Out of the 248,230 reports which met the eligibility criteria and were retained, 14,536 
reports (5.9%) met the inclusion criteria for being cases and 233,694 reports (94%) 
were considered as non-cases (Figure 1). 
r 
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5.1.1.2 Exposure status 
A total of 5,616 reports were considered exposed to either clarithromycin or 
azithromycin in this study, since they inc1uded a mention of these drugs among the 
suspected medications for the adverse event. 
Out of the 14,536 reports retained as cases in the study, 65 (0.4%) reports had a 
mention of azithromycin as the suspected medication, 270 (1.9%) had a mention of 
c1arithromycin and 14,201 mentioned other drugs. Out of 233,694 reports retained as 
non-cases in the study, 1,010 (0.4%) reports had a mention of azithromycin as the 
suspected medication, 4,271 (1.9%) reports had a mention of c1arithromycin and 
228,413 mentioned other drugs (Figure 1). 
5.1.1.3 Characteristics of Cases and Non-Cases 
The distribution of exposure status among cases and non cases are reflected in Table 
4. The age distribution and sex ratio amongst cases and non cases is also depicted. 
As' expected, for the entire study population, the elderly accounted for the greatest 
proportion of spontaneous reports. However, the age distribution within cases and 
non-cases was slightly heterogeneous. The proportion of reports involving elderly 
patients was lowest for those ascribed to azithromycin (p<.OOI) than for 
clarithromycin or for the other drugs (the non-cases). On the other hand, the sex ratio 
for cases and non-cases was very similar. 
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For aIl compansons, the relative reporting ratios or proportional reporting ratios 
(Table 3) of the association between cardiac effect and the use of azithromycin or 
c1arithromycin and 95% confidence intervals are shown in Tables 5 to 10. 
The proportional reporting ratio of the association between cardiac effect and the use 
of azithromycin was estimated at 1.033. Its 95% confidence interva1 ranged from 
0.80 to 1.33 (see Table 5). The proportional reporting ratio of the association 
between cardiac effect and the use of c1arithromycin was estimated at 1.015. Its 95% 
confidence interval ranged from 0.90 to 1.15 (see Table 6). 
Point estimates were greater for females than males, however, the difference is not 
significant because of overlappingconfidence intervals. The proportional reporting 
ratio of the association between cardiac effect and the use of azithromycin in men 
was estimated at 0.77. Its 95% confidence interval ranged from 0.53 to 1.11 
(p=0.1399) (see Table 7). The proportional reporting ratio of the association between 
cardiac effect and the use of azithromycin in women was estimated at 1.36. Its 95% 
confidence interval ranged from 0.96 to 1.92 (p=0.0600) (see Table 8). 
The proportional reporting ratio of the association between cardiac effect and the use 
of c1arithromycin in men was estimated at 0.878. Its 95% confidence interval ranged 
from 0.73 to 1.06 (p= 0.1404 (see Table 9). The proportional reporting ratio of the 
association between cardiac effect and the use of c1arithromycin in women was 
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estimated at 1.166. !ts 95% confidence interval ranged from 0.99 to 1.38 (p=0.0575) 
(see Table 10). 
A multivariate logistic regression model was used to adjust for age (table Il) 
showing a trend that gender modified the measure of association. Female gender 
appeared to have consistently higher association to cardiac events than males. 
5. 1. 1. 4.Figures and Tables 
Figure 1. Depiction of Breakdown of Reports from Working Database 
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(1) The 248,230 reports retain~d in the study were distributed as follows according to study year; 
1992 = 42,830 reports; 
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1996 = 48,998 reports; 
1997 = 23, 954 reports. 
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Figure 2. Reasons for Exclusions and the Corresponding Number of Reports 
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Table 4. Characteristics of the Spontaneous Reports Involving Cardiac 
Conditions 
Ascribed to Ascribed to Ascribed to P value 
azithromycin c1arithromycin other drugs 
(N = 65) (N = 270) (N = 14201) 
Age Group 
18-34 7 (11%) 39 (14%) 1718 (12 %) 
35-44 18 (28 %) 34 (13 %) 1666 (12 %) 
45-64 16 (25 %) 64 (24 %) 4298 (30 %) 
65+ 24 (37 %) 133 (49 %) 6519 (46 %) 0.0014 
Gender 
Male 30 (46%) 122 (45 %) 7417 (52 %) 
Female 35 (54%) 148 (55 %) 6784 (48 %) 0.0454 
Table 5. 2X2 Contingency Table used for the Calculation of Proportion al 
Reporting Rates: Cardiac Events and the use of Azithromycin 
Cardiac Event 
No Cardiac Event (other 
Total 
ADEs) 
Azithromycin 65 1010 1075 
AlI Other Drugs 14201 228413 242614 
PRR=[(65/l 075)/(1420 1/242614)] 
Table 6. 2X2 Contingency Table used for the Calculation of Proportional' 
Reporting Rates: Cardiac Events and the use of Clarithromycin 
Cardiac Event 
No Cardiac Event (other 
Total 
ADEs) 
Clarithromycin 270 4271 4541 
Ali Other Drugs 14201 228413 242614 
PRR=[(270/4541 )/(1420 1/242614)] 
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Table 7. 2X2 Contingency Table used for the Calculation of Proportional 
Reporting Rates: Cardiac Events and the use of Azithromycin in Men 
No Cardiac Event (other 
Cardiac Event Total 
ADEs) 
Azithromycin 30 532 562 
Ali Other Drugs 7417 99699 107116 
PRR=[(30/562)/(74171107116)] 
Table 8. 2X2 Contingency Table used for the Calculation of Proportion al 
Reporting Rates: Cardiac Events and the use of Azithromycin in Women 
Cardiac Event 
No Cardiac Event (other 
Total 
ADEs) 
Azithromycin 35 478 513 
Ali Other Drugs 6784 128714 135498 
PRR=[(35/513 )/(6784/135498)] 
Table 9. 2X2 Contingency Table used for the Calculation of Proportional 
Reporting Rates: Cardiac Events and the use of Clarithromycin in Men 
Cardiac Event 
No Cardiac Event (other 
Total 
ADEs) 
Clarithromycin 122 1884 2006 
AlI Other Drugs 7417 99699 107116 
PRR=[ (122/2006)/(7 417 /1 07116)] 
Table 10. 2X2 Contingency Table used for the Calculation of Proportional 
Reporting Rates: Cardiac Events and the use of Clarithromycin in Women 
Cardiac Event 
No Cardiac Event (other 
Total 
ADEs) 
Clarithromycin 148 2387 2535 
AlI Other Drugs 6784 128714 135498 
PRR=[(14812325)/(6784/135498)] 
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Table 11. Multivariate Analysis with Multiple Logistic Regression 
Parameter Odds Ratio (adj) 95% CI 
Age Group: 18-34 
Gender 
Male (Ret) 1 1.4_21-1.727 
Female 1.566 
Age Group: 35-44 
Gender 
Male (Ret) 1 1.085-1.318 
Female 1.196 
Age Group: 45-64 
Gender 
Male (Ret) 1 1.264-1.430 
Female 1.344 
Age Group: 65+ 
Gender 
Male (Ret) 1 1.119-1.238 
Female 1.177 
AdJusted for medlcatlOll use 
5.2 RAMQ database 
5.2.1 Study Population 
Using the data from 4000 patients selected for analysis and provided from the 
RAMQ, patterns of drug usage were characterized according to mean duration of use 
and mean dosage (dependent variables) as shown in Table 12, 14, 15 and 17. These 
were derived from the following data readily available in the database: date of 
dispensinglservice, prescribed duration of treatment (days), quantity of medication 
dispensed, dosage. Us ers of both clarithromycin and azithromycin were similar in 
patterns of drug use. 
Men and women were also compared with respect to patient characteristics (history 
of cardiac medication, examination/procedure related to cardiology and diagnosis of 
cardiac conditions) (Table l3 and 16). Independent variables were gender, age, and 
patient medical history. Users of both clarithromycin and azithromycin were similar 
in patient characteristics. 
Differences in the profile users were determined by comparing sex ratios, mean age, 
and patient medical history (Table 12, l3, 15, and 16). A P value was ca1culated 
comparing gender in each category. Overall, for users of both clarithromycin and 
azithromycin, there is not much difference in the patterns of drug use and patient 
characteristics between males and females (OR about 1) in terms of dosage, duration 
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of use, history of cardiac medication, examination/procedure related to cardiology 
and diagnosis of cardiac conditions. 
5.2.1.1 Tables 
Table 12. Description ofUsers - Zithromax (azithromycin) 
Males Females P value 
0/0 39.8 60.2 <.0001 
Age (year), mean (s.d.) 73.2 (5.7) 73.5 (5.6) 0.162 
Starting Dose (mg/day), 307.1 (63.4) 310.4 (85.2) 0.238 
mean (s.d.) 
Table 13. Medical History - Zithromax (azithromycin) 
Cardiac Events (in previous Males Females Pvalue 
year) (n = 796) (n = 1204) 
At least 1 Cardiac Medication (in 477 (60%) 754 (63%) 0.243 
previous year) 
At least 1 ExaminationIProcedure 27 (3.4%) 27 (2.2%) 0.158 
related to cardiology 
Diagnosis of cardiac condition 367 (46%) 573 (48%) 0.544 
Table 14. Patterns of Use (with 1 year follow-up) - Zithromax (azithromycin) 
Males Females P value 
Starting Dose (mg/day) (s.d.) 392.0 (309.7) 388.1 (203.3) 0.295 
Duration of Use (days), mean 7.0 (8.6) 6.5 (5.0) 0.174 
(s.d.) 
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Table 15. Description of Users - Biaxin (clarithromycin) 
Males Females P value 
0/0 41.71 58.29 <.0001 
Age (year), mean (s.d.) 73.1 (5.5) 73.5 (5.7) 0.157 
Starting Dose (mg/day), 637.5 (233.5) 604.7 (214.5) 0.275 
mean (s.d.) 
Table 16. Medical History - Biaxin (clarithromycin) 
Cardiac Events (in previous Males Females P value 
year) (n = 901) (n = 1259) 
At least 1 Cardiac Medication (in 525 (58%) 787 (63%) 0.051 
previous year) 
At least 1 Examination/Procedure 20 (2.2%) 26(2.1%) 0.925 
related to cardiology 
Diagnosis of cardiac condition 426 (47%) 594 (47%) 0.998 
Table 17. Patterns of Use (with 1 year follow-up) - Biaxin (clarithromycin) 
Males Females P value 
Starting Dose (mg/day) (s.d.) 843.1 (958.5) 790.9 (574.9) 0.385 
Duration of Use (days), mean 12.7 (15.6) 12.7 (12.6) 0.147 
(s.d.) 
6. Discussion 
A major function of spontaneous reporting is generating new 'signaIs'. For this 
purpose, the FDA spontaneous reporting database has become the primary data 
resource for the study and identification of preliminary signaIs such as new and 
unexpected ADRs and was used in this research to assess the association between 
azithromycin and clarithromycin and possible cardiac effects and gender influence 
that may not have been recognized during their clinical development. The 
proportional reporting ratios were used to determine whether a cardiac event occurred 
more frequently among patients treated with the macrolide than among patients 
treated. with other drugs and presenting other ADRs, in particular, in a more 
vulnerable patient subgroup, Le. female gender. 
According to literature, female gender appears to be a risk factor for cardiac effects 
[5, 7, 8, 21, 22]. In this research, point estimates were greater for females than males, 
indicating greater association between cardiac effect and the use of azithromycin or 
clarithromycin. The difference, however, was not significant because of overlappihg 
confidence intervals. Due to the rarity of exposed events, a statistically significant 
gender difference in the reporting of cardiac effects could not be found in this study. 
A non significant difference was observed with the azithromycin group which could 
have been a problem of statistical power because of small sample size. Although, 
also observed with clarithromycin which had a much greater sample size. 
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Although PRR < 3, which may be indicative of background noise and therefore, not 
be representative of a signal, surveillance of a patient cohort in real life may be 
considered in order to increase the detection of ADRs and avoid the use of data based 
solely on spontaneous reports. 
A multivariate logistic regression model was also used to adjust for age, showing a 
trend that gender modified the measure of association. Female gender appeared to 
have consistently higher association to cardiac events than males, in aIl age groups. 
In the highest age group (i.e. 65 +), however, the noted gender difference decreased 
and age may have become the dominant factor. In aIl individuals, pharmacology and 
pharmacokinetic activity change with time, therefore, age was an important factor for 
which to adjust. It was not possible to adjust for dosage, since dosage equivalence 
do es not exist for aIl the other drugs (i.e. the unexposed group). It was also not 
possible to compute due to the high number of reports with missing information for 
dosage. 
Crude estimates were determined to be non significant whereas the adjusted were 
determined as significant. In a field where knowledge may be derived from scanty 
information, the need for additional systematic surveillance may be considered so as 
to avoid the sole use of data based on widely differing quality. 
In order to determine whether there may have been a confounding effect in the 
patterns of use or medical history between gender, the RAMQ database was used 
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un der assumption that gender differences would be similar to those found in the US, 
i.e. the population targeted by the FDA database. OveraIl, for users of both 
clarithromycin and azithromycin, there is not mu ch difference in the patterns of drug 
use and patient characteristics between males and females (OR about 1) in terms of 
dosage, duration of use, history of cardiac medication, examination/procedure related 
to cardiology and diagnosis of cardiac conditions. 
Compared to erythromycin, the newer macrolides (i.e. azithromycin and 
clarithromycin) have been developed in an effort to improve the antimicrobial 
spectrum as weIl as the pharmacokinetics and tolerability [54] of the drug. In our 
research, however, female gender, although not statistically significant, appeared to 
have consistently higher association to cardiac events than males. As a preliminary 
experiment, the findings may need to be further explored as there were limitations 
and biases associated with the use of the FDA spontaneous database. 
6.1 InternaI Validity 
In general, as with the analysis of adverse drug reactions, selection bias might be 
present, since certain ADRs are more likely to be reported than others. It is known 
that not aIl ADRs are reported. In our study, reporting bias may have been present in 
the cases where cardiac eveJ}ts were more serious and more likely to be discovered, 
discussed with health professionals and subsequently reported, in comparison to other 
less ser(ous events. Factors such as severity, novelty and media coverage have been 
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found to be associated with reporting. AIso, women tend to see their physicians more 
often than men and, therefore, possibly report more ADRs. This latter effect should 
have been controlled for by the use of a non-case (control) group. 
Another point of attention is confounding. Due to the observational nature of this 
study, certain types of systematic eITors may have influenced the results of the study. 
In aIl individuals, pharmacology and pharmacokinetic activity change with time, 
therefore, age was an important factor to take into consideration. A multivariate 
logistic regression model was used to adjust for age (Table Il). Other potentially 
confounding factors such as body weight, history of cardiovascular problems (e.g. 
hypertension), smoking status could not be collected, since the information was not 
available. It was not possible to control for history of cardiovascular problems or 
family history of cardiovascular problems, because this information was not recorded 
in these reports. Marker drugs could not be used to assess the presence of CUITent 
cardiovascular problems (e.g. hypertensive medications as an indicator of 
/ 
hypertension). ,However, these factors would only be confounders if they were also 
associated with the exposure of interest, either exposure to azithromycin or 
c1arithromycin, or for the sub-study, gender. Confounding was more likely to be 
problematic with gender given that men are more likely to be smokers or have 
cardiovascular problems than females. It is imperative that moving forward more 
work needs to be done in ensuring the quality of reports and information contained 
within a pharmacovigilance database (see Section 6.3). 
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6.2 External Validity 
An association between the drug (i.e. antibiotic) and the observed event could not be 
assumed with aIl spontaneously reported events. The causal relationship between 
drug exposure and adverse event reported to the FDA is not individually evaluated 
for the vast majority of ADR reports. In this study, we could not record the latent 
period between exposure and cardiac effect development. Additional studies need to 
be done to confirm a true pharmacodynamic or pharmacokinetic interaction and to 
determine the strength of this association in daily practice. The various degrees of 
underreporting, associated with spontaneous reporting, make it difficult to estimate 
the true incidence of a possible gender effect on cardiac event development. 
Another important limitation to spontaneous reports is the limited access to certain 
patient data. For reasons of confidentiality, no patient identifiers could be provided, 
therefore, not allowing us to ob tain follow-up information or track patient specific 
information from other sources such as hospital medical records, etc. Smoking could 
also not be accounted for adequately since lifetime exposure to cigarettes, an 
important risk factor, would be impossible to determine from our data collection. 
However, if smoking is a confounder, it should bias the results towards the null (i.e. 
lead to a conservative estimate) since a greater proportion of men in this age group 
smoke than women. 
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Information was missing to various degrees with the spontaneous data reported. The 
amount of missing information may differ between more serious adverse events (i.e. 
cardiac events) versus non-serious events. Potentially, more data could be available 
for unhealthier patients and hence a differential information bias. Even though this 
lack of information may exist, this should not play an important role in the results, 
1 
since this should be observed in both the male and female groups. 
In this study, the classification of whether a patient experienced a cardiac event was 
based solely on the report of the physician; the diagnosis could not be confirmed by 
additional tests. Furthermore, the reports originate from physicians whose ability to 
diagnose cardiac events may vary. Therefore, the risk of over- diagnosing these 
events exists. Misclassification, however, is not expected to be different between 
men and women. Consequently, one would expect that this non-differential 
misclassification results in a bias towards the null [36]. 
The RAMQ database provided us with data on antibiotics use among Quebec elderly 
outpatients, which could differ from the US population. As gender differences in 
drug use arose, we would put them into perspective as potential confounders using 
the case/non-case results among the 65 years old and over. While it is plausible that 
regional differences exist in drug use, gender differences are not expected to be 
reversed completely from countries as close as those of Canada and the US. 
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6.3 N ecessity of Good Pharmacovigilance 
The epidemiological approach used in this research was a rapid and inexpensive way 
to investigate the possible gender effect associated with antibiotic drug use, not 
discovered during clinical trials and perhaps may also have been used as guidance in 
determining next steps. It is imperative that moving forward more work needs to be 
do ne in ensuring the quality of reports and information contained within a 
pharmacovigilance database. Spontaneous case reports of adverse events submitted 
to the manufacturer and FDA, and reports from other sources, such as the medical 
literature or clinical studies, may generate signaIs of adverse effects of drugs. The 
quality of the reports is critical for appropriate evaluation of the relationship between 
the product and adverse events. FDA recommends that sponsors make a reasonable 
attempt to ob tain complete information for case assessment during initial contacts and 
subsequent follow-up, especially for serious events and encourages manufacturers to 
use trained health care practitioners to query reporters. Computer-assisted interview 
technology, targeted questionnaires, or other methods developed to target specific 
events can help focus the line of questioning. When the report is from a consumer, it 
is often important to obtain permission to contact the health care practitioner familiar 
with the patient's adverse event to obtain further medical information and to retrieve 
relevant medical records, as needed. 
FDA suggests that the intensity and method of case follow-up be driven by the 
seriousness of the event reporte d, the report's origin (e.g., health care practitioner, 
patient, literature), and other factors. FDA recommends that the most aggressive 
follow-up efforts be directed towards serious adverse event reports, especially of 
adverse events not known to occur with the drug. 
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Improving the quality of spontaneous reports and ensuring good pharmacovigilance 
will reduce the present limitations and biases which exist and improve the reliability 
of signaIs detected and moving forward with confirmatory studies or actions will be 
taken with more certainty. In addition, a prospective follow-up of a patient cohort in 
real life may be considered in order to increase the detection of ADRs and avoid the 
use of data based solely on spontan'eous reports. 
6.4 Future Direction 
The product information provided to health care professionals, for both 
clarithromycin and azithromycin, indicates the potential risk of cardiac events 
including developing cardiac arrhythmia and torsades de pointes (TdP), however, no 
gender effect is noted. As a subsequent action, this research may warrant the addition 
of new information so as to maximize the level of understanding by health 
professionals and provide more accurate product information in order to ensure 
patient safety, in particular, in more vulnerable patient subgroups, such as female 
gender. 
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A next step may be the consideration of a pharmacovigilance plan. Consideration of 
a prospective follow-up of a patient cohort in real life may be considered in order to 
increase the detection of ADRs and avoid the use of data based solely on spontaneous 
reports. Active surveillance, contrary to passive surveillance (i.e. spontaneous 
reporting), may seek to as certain completely the number of ADRs via a continuous 
pre-organized process (e.g. drug-event monitoring, registry). Comparative 
observational studies or targeted clinical investigations can also be considered. 
In addition, systematically conducting drug utilization studies with routine 
pharmacovigilance signal detection may be considered as an attempt to add context to 
any findings and be used as a tool for therapeutic risk management. It may be 
considered that drug utilization studies be systematically conducted at marketing so 
that such data are readily available and not wait until a signal is detected to conduct 
them on a post-hoc basis. 
7. Conclusion 
Spontaneous databases can serve as an early wammg mechanism to signal the 
existence of adverse events that were not detected during c1inical trials. In most 
cases, it is the only early signaling method available for newly marketed drugs. Data 
mining, such as the case/non-case method, being used to search for signaIs in the US 
FDA AERS database, provides more accurate prescribing information for health 
professionals. A general use of such methods should be considered within 
institutions or industry, resulting in the improvement of early detection of signaIs 
within such databases. 
SignaIs of potential safety problems with marketed medicines represent a broad 
spectrum of severity and impact on public health. Most signaIs will not merit the 
type of formaI benefit-risk evaluation proposed here, though the concepts are 
regarded as generally useful in any periodic or special evaluation of relative benefits 
and risks. The appearance of new b~t relatively insignificant adverse reaction may 
require only a routine change in product information (data sheets, labeling etc.). As a 
next step, a prospective follow-up of a patient cohort in real life may have also been 
considered in order to increase the detection of ADRs and avoid the use of data based 
solely on spontaneous reports. 
In addition, systematically conducting drug utilization studies with routine 
pharmacovigilance signal detection may be considered as an attempt to add context to 
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any findings. Although signal detection is routinely done in phannacovigilance 
databases, results that are published or that are sent to regulatory authorities (e.g. 
periodic safety update reports or a summary of safety data) are rarely accompanied by 
a drug utilization study. Only reporting rates are submitted, with denominators that 
are derived from the drug sales data. If the study had found differences in patterns of 
utilization across genders, then it may bring sorne evidence (and reassure) authorities 
that females may not be a sub-population at risk for this drug-event relationship. We 
may consider phannacovigilance signal detection in spontaneous reporting databases, 
accompanied by drug utilization studies, to be used as a tool for therapeutic risk 
management. It may be considered that drug utilization studies be systematically 
conducted at marketing so that such data are readily available and not wait until a 
signal is detected to conduct them on a post-hoc basis. 
This epidemiological model investigated the effect of a potential effect modifier (i.e. 
gender) not discovered during clinical trials and perhaps may be used as a predictor 
of functional and phannacologic differences between men and women. 
Understanding the potential mechanisms responsible for the greater risk of cardiac 
events (e.g. drug-induced arrhythmias) in women could lead to screening methods for 
identification of individuals at risk for drug-induced cardiac events (e.g. arrhythmias) 
or to the development of drugs with reduced risk of inducing cardiac events (i.e. 
arrhythmias ). 
76 
Ultimately, in this discussion, the goal 1S to provide safer and more effective 
treatments with more accurate prescribing information for health care professionals 
and for al! patients. In today's environment, health authorities, industry and 
institutions, in a joint collaboration, should continue to monitor the marketplace and 
work together to improve the risk management of marketed medicines. 
8. Infra-structure and budget 
• FDA spontaneous reporting database: available through Pfizer 
• Statisticians for data extraction + consultation for data analysis: available through 
Pfizer 
• RAMQ database: $5700.00 (+taxes); Partially funded by FRSQ young 
investigator award (Y. Moride) and unrestricted grant from Pfizer Canada Inc. 
• Software and computer facilities were available through the Faculty of Pharmacy 
Epidemiology Computer Laboratory (Dr. Moride). 
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